Kamaljeet Kaur, Raja Fayad, Arpit Saxena, Norma Frizzell, Anindya Chanda, Suvarthi Das, Saurabh Chatterjee, Shweta Hegde, Manjeshwar Shrinath Baliga, Venkatesh Ponemone, Matthew Rorro, Jennifer Greene, Yasmine Elraheb, Alan J Redd, John Bian, John Restaino, LeAnn B Norris, Zaina P Qureshi, Bryan L Love, Brandon Brookstaver, Peter Georgantopoulos, Oliver Sartor, Dennis W Raisch, Gowtham Rao, Kevin Lu, Paul Ray, William Hrusheshky, Richard Schulz, Richard Ablin, Virginia Noxon, Charles L Bennett
BACKGROUND: The 3 fluoroquinolone (FQ) antibiotics - ciprofoxacin, levofoxacin, and moxifoxacin - are commonly administered to oncology patients. Although these oral antibiotics are approved by the US Food and Drug Administration (FDA) for treatment of urinary tract infections, acute bacterial sinusitis, or bacterial infection in patients with chronic obstructive pulmonary disease, they are commonly prescribed off-label to neutropenic cancer patients for the prevention and treatment of infections associated with febrile neutropenia...
February 2016: Journal of Community and Supportive Oncology